Advertisement

Topics

Latest "ObsEva Starts Phase Clinical Program Nolasiban" News Stories

19:16 EST 16th November 2018 | BioPortfolio

Here are the most relevant search results for "ObsEva Starts Phase Clinical Program Nolasiban" found in our extensive news archives from over 250 global news sources.

More Information about ObsEva Starts Phase Clinical Program Nolasiban on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ObsEva Starts Phase Clinical Program Nolasiban for you to read. Along with our medical data and news we also list ObsEva Starts Phase Clinical Program Nolasiban Clinical Trials, which are updated daily. BioPortfolio also has a large database of ObsEva Starts Phase Clinical Program Nolasiban Companies for you to search.

Showing "ObsEva Starts Phase Clinical Program Nolasiban" News Articles 1–25 of 25,000+

Friday 16th November 2018

Alphamab Oncology Completes Series-A Round Financing - Further Strengthening Its Global Innovative Biologics Platforms

SUZHOU, China, Nov. 17, 2018 /PRNewswire/ -- Alphamab Oncology announced the successful completion of series A financing round, with more than $100 million raised. A number of well-regarded institutional investors, including Advantech Capital, PAG, China Venture Capital Fund[1], OrbiMed, Heritage Provider Network and Janchor Partners, participated in the financing. Alphamab Oncology plans to use...


Kala Pharmaceuticals Inc KALA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryKala Pharmaceuticals Inc Kala Pharmaceuticals is a clinical stage pharmaceutical company that offers nanoparticlebased treatments for ocular diseases affecting both front and back of the eye. The company's lead program MPP nanosuspension of an ophthalmic corticosteroid is under phase III clinical development for the treatment of postsurgical inflammation, meibomian gland disease, ocular inf...

Norgine BV Medical Equipment Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryNorgine BV Norgine is a pharmaceutical company that offers medicinal products. The company develops drugs in the therapeutic areas of gastroenterology, incontinence, hepatology and critical and supportive care and pain management, among others. It offers the treatment of diseases related to gastrointestinal tract, gastric and hepatic conditions, critical and supportive care. Norgine offers ...


Make-a-Wish program tied to lower hospital costs for sick kids https://reut.rs/2DJ1Ce2 

Make-a-Wish program tied to lower hospital costs for sick kids https://reut.rs/2DJ1Ce2 

Novel Agent Active Across Heavily Pretreated HER2+ Tumors

The novel bispecific antibody ZW25 induced a disease control rate of 82% in heavily pretreated patients across several HER2-positive tumor types, according to phase I study results presented at the 2018 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium.

CryoPort Inc CYRX Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryCryoport, Inc. Cryoport is a provider of cold chain logistics solutions for temperaturesensitive biological materials to the life science industries. It offers liquid nitrogen dry vapor shippers with advanced logistics management platform called Cryoportal, which provides credentials related to the shipment. It also offers SmartPak II condition monitoring system that provides information re...

Capivasertib Effective in AKT-Mutated Cancers

The investigational AKT inhibitor capivasertib (AZD5363) demonstrated clinical activity in patients with AKT-mutated cancers, suggesting the validity of tailoring treatment to tumor genes. 

Make-a-Wish program tied to lower hospital costs for sick kids

(Reuters Health) - Kids with life-threatening illnesses who receive a special gift from the Make-a-Wish Foundation may have lower hospital costs than sick children who don't get these gifts, a U.S. study suggests.

In Phase III trial of Imfinzi for a form of #lungcancer, @AstraZeneca's Imfinzi misses 2nd primary endpoint of overall survival: http://ow.ly/HZBi30mDX6U 

In Phase III trial of Imfinzi for a form of #lungcancer, @AstraZeneca's Imfinzi misses 2nd primary endpoint of overall survival: http://ow.ly/HZBi30mDX6U 

AMIA Calls for Harmonization of Data Privacy Policies

As the lines between consumer and clinical data systems continues to blur, there is a need to harmonize health sector data privacy policy, such as HIPAA, and consumer data policy to develop a new era of privacy policy, according to the American Medical Informatics Association (AMIA).

$ARQL Presents Clinical and Preclinical Data for ARQ 751 at #ENA18 https://www.businesswire.com/news/home/20181116005501/en/ArQule-Presents-Clinical-Preclinical-Data-ARQ-751 …

$ARQL Presents Clinical and Preclinical Data for ARQ 751 at #ENA18 https://www.businesswire.com/news/home/20181116005501/en/ArQule-Presents-Clinical-Preclinical-Data-ARQ-751 …

ArQule Presents Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium

Three poster presentations demonstrate ARQ 751’s potential as both a monotherapy and in combination with other anti-cancer agents ArQule, Inc. (Nasdaq: ARQL) today announced the presentation of clinical and preclinical data on ARQ 751 in three poster presentations at the 30th EORTC/AACR/NCI Symposium held from November 13 to 16, 2018 in Dublin, Irela...

United Imaging Healthcare Announces Appointment of World-Renowned Expert as Senior Scientific Advisor

Prof. Dr. Hermann Requardt to provide strategic guidance on technology and R&D SHANGHAI, Nov. 16, 2018 /PRNewswire/ -- United Imaging Healthcare Co., Ltd. (UIH), an international leader in advanced medical imaging and radiotherapy equipment, today announced the appointment of Hermann Requardt, Ph.D., former Chief Executive Officer of Siemens Healthcare, as it...

IFPBM Presents Patient Blood Management to the U.S.-China Health Summit

BEIJING, Nov. 16, 2018 /PRNewswire/ -- Dr. Alex Hofmann, a trustee of the International Foundation for Patient Blood Management, recently spoke at the U.S.-China Health Summit held in Beijing, China, on October 12-14, 2018. Initiated by Yuanli Liu, Director of 'Harvard China Initiative,' and Dr. Jing Ma, Professor at Harvard Medical School, the Summit was inaugurated at Harvard Univ...

Living Cell Technologies Ltd LCT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryLiving Cell Technologies Ltd LCT is a biotechnology company that develops cellbased therapeutics for the treatment of neurological diseases, diabetes, and stroke and hearing loss. It focuses on discovering regenerative treatments which restore function using naturally occurring cells. LCT develops its candidates based on its proprietary encapsulation technology, Immupel. Its lead product ca...

GI Dynamics Announces Close of Second Tranche of Placement and Grant of Options to CEO

GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to announce that, following stockholder approval obtained on 30 October 2018 at the Company’s Special Meeting, it has successfully completed the issue of the CHESS Depositary Interests (CDIs), the subject of the second tranche of the Placement that was det...

Asthma Pipeline Review, H2 2018 [Report Updated: 31102018] Prices from USD $2500

Asthma Pipeline Review, H2 2018SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Asthma Pipeline Review, H2 2018, provides an overview of the Asthma Respiratory pipeline landscape.Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breat...

The launch of a clinical trial testing whether experimental #Ebola therapies improve patients’ chances of survival is a landmark moment in responding to the current and future crises. https://buff.ly/2Q7GaFm 

The launch of a clinical trial testing whether experimental #Ebola therapies improve patients’ chances of survival is a landmark moment in responding to the current and future crises. https://buff.ly/2Q7GaFm 

Hypereosinophilic Syndrome Pipeline Review, H2 2018 [Report Updated: 13112018] Prices from USD $2000

Hypereosinophilic Syndrome Pipeline Review, H2 2018SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypereosinophilic Syndrome Pipeline Review, H2 2018, provides an overview of the Hypereosinophilic Syndrome Hematological Disorders pipeline landscape."The hypereosinophilic syndrome HES is a disease characterized by a persistently elevated eosinophil coun...

GSK confirms significant investments in UK manufacturing: Ulverston in Cumbria selected as site of new biopharmaceutical factory

Following an extensive feasibility study conducted through 2011, GSK today announced that the location for its new state-of-the-art biopharmaceutical manufacturing facility will be Ulverston, Cumbria. Approximately £350m has been earmarked for its construction. Four existing GSK sites across the UK were assessed – Barnard Castle and Ulverston in the North of England, and Irvine and Mon...

South Tees Hospitals NHS Foundation Trust wins prestigious Bionow Healthcare Project of the Year Award

A partnership between industry and South Tees Hospitals NHS Foundation Trust has been awarded the prestigious Bionow Healthcare Project of the Year Award for the development and delivery of a clinical research study examining the management of pre-operative oedema in ankle fracture patients.To celebrate the win, the Trust has today been formally presented with the Bionow award, which recognises th...

Ontario Bioscience Innovation Organization Announces a Call for Applications for the 2019 Capital Access Advisory Program (CAAP®)

The Ontario Bioscience Innovation Organization (OBIO®), the leading advocate for Ontario’s health science industry, is pleased to announce a call for applications for the 2019 OBIO Capital Access Advisory Program (CAAP®). OBIO CAAP is a unique, industry-led initiative that provides selected high-potential Ontario health science companies with ...

NanoSphere Announces $2.25 Million Financing for Rapid Expansion of Cannabis Product Line

NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) is pleased to announce a non-brokered private placement of up to CAD $2,250,000. The proceeds will be used to expand the award-winning Evolve Formulas cannabis products into more markets in the US, Canada, and outside of North America. Funds will also be used to develop new products, increase ...

NRMP Releases Report on Applicant Qualifications that Foster Fellowship Match Success

WASHINGTON, Nov. 16, 2018 /PRNewswire/ -- The National Resident Matching Program (NRMP®) announces the release of Charting Outcomes in The Match: Specialties Matching Service®, Appointment Read more...

Ascend Hospice Recognized as a We Honor Veterans Partner

Ascend Hospice agencies partner with We Honor Veterans CRANFORD, N.J. (PRWEB) November 16, 2018 It may surprise many people to learn that 25 percent of those who die every year in the U.S. are Veterans. To help provide care and support that reflect the important contributions made by these men and women, all Ascend Hospice agencies have become a national partner of We Honor Veterans, a pioneering...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks